The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide. 
Clinical Roundup

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

Chronic, low-grade inflammation in the body—a phenomenon known as “inflammaging” because it increases with age—has been linked to many leading causes of illness and death, including cancer, heart disease, metabolic conditions, and neurodegenerative diseases. But scientists have struggled to understand what causes inflammaging or how to reverse its effects.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account